Previous Article | Next Article 
Journal of Virology, February 2000, p. 1158-1167, Vol. 74, No. 3
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Activation of the Mitogen-Activated Protein Kinase
p38 by Human Cytomegalovirus Infection through Two Distinct Pathways: a
Novel Mechanism for Activation of p38
Robert A.
Johnson,1,2
Shu-Mei
Huong,2 and
Eng-Shang
Huang1,2,3,4,*
Department of Microbiology and
Immunology,1 Lineberger Comprehensive
Cancer Center,2 Department of
Medicine,3 and Curriculum of Genetics
and Molecular Biology,4 University of North
Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7295
Received 28 July 1999/Accepted 1 November 1999
 |
ABSTRACT |
Recent evidence indicates activated mitogen-activated protein
kinase (MAPK) p38 has a critical function in human cytomegalovirus (HCMV) viral DNA replication in infected human fibroblasts. To elucidate the mechanism of HCMV-mediated p38 activation, we have performed a detailed analysis of p38 activation and the kinases associated with this activation at different times postinfection. We
demonstrate that p38 kinase activity is strongly increased following
viral infection. Inhibition of this activity significantly inhibited
HCMV-induced hyperphosphorylation of pRb and phosphorylation of heat
shock protein 27, suggesting that p38 activation is involved in
virus-mediated changes in host cell metabolism throughout the course of
infection. We then provide evidence that p38 activation is mediated by
different mechanisms at early times versus later times of infection. At
early times of infection (8 to 14 h postinfection [hpi]), when
p38 activation is first observed, no significant activation of the
three kinases which can directly phosphorylate p38 (namely, MKK3, MKK6,
and MKK4) is detected. Using vectors which express dominant negative
proteins, we demonstrate that basal MKK6 kinase activity is necessary
for HCMV-mediated p38 activation at these early times of infection (12 hpi). Then, we use ATP depletion to show that at 12 hpi, HCMV inhibits
dephosphorylation of activated p38. These two experiments suggest that
HCMV activates p38 by inhibition of dephosphorylation of p38. In
contrast to early times of infection, at later times of infection (48 to 72 hpi), increased MKK3/6, but not MKK4, activity is observed. These results indicate that at early times of HCMV infection, increased steady-state levels of activated p38 is mediated at least in part by
inhibition of dephosphorylation of p38, while at later times of
infection p38 activation is due to increased activity of the upstream
kinases MKK3 and MKK6. These findings indicate that HCMV has developed
multiple mechanisms to ensure activation of the MAPK p38, a kinase
critical to viral infection.
 |
INTRODUCTION |
Human cytomegalovirus (HCMV) is a
ubiquitous betaherpesvirus that is found in over 80% of the
population. While asymptomatic in most immunocompetent hosts, in
immunocompromised individuals, such as transplant recipients and AIDS
patients, HCMV causes a wide range of clinical symptoms which, if left
untreated, are often fatal (6, 17). Currently, patients are
treated with antiviral drugs, such as ganciclovir and Foscarnet, which
inhibit HCMV-permissive infection (33, 37, 40). However,
with the dramatic rise in immunocompromised individuals who require
long-term antiviral treatment, drug-resistant strains of HCMV are
becoming more common, resulting in a loss of ability to control
infection (reviewed in reference 12). This problem
has resulted in the need to identify and characterize new antiviral
targets which can be used to inhibit the life cycle of HCMV.
Several reports have demonstrated that HCMV infection induces
activation of numerous host cell transcription factors such as Sp-1,
CREB/ATF family members, and NF-
B (7, 20-22, 30, 56-58). This activation ensures high levels of expression of the many viral and cellular genes which are required for completion of the
lytic life cycle. Since many of these transcription factors are
required for expression of certain genes, and hence are necessary for
completion of the viral life cycle, inhibiting their activation represents one mechanism to inhibit viral infection.
One way to inhibit the activation of cellular transcription factors may
be to inhibit upstream signaling events which control their activity.
Since the transactivation function of many cellular transcription
factors is at least partially regulated by phosphorylation events,
identifying and inhibiting cellular kinases which phosphorylate transcription factors may represent one mechanism to inhibit HCMV permissiveness (2, 49). This has led members of our
laboratory and others to search for specific kinase pathways which are
activated following HCMV infection and which activate transcription
factors. Mitogen-activated protein kinases (MAPKs) are examples of
kinases which activate numerous transcription factors, and some members of the MAPK family are strongly activated following HCMV infection (19, 46).
MAPKs are important cellular signaling kinases which are activated by
dual phosphorylation on specific tyrosine and threonine residues in
response to various external and internal stimuli (reviewed in
references 10 and 45). In
mammalian cells, three general groups of MAPKs have been identified:
extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal
kinase (JNK), and p38/Hog. Each MAPK is positioned at the bottom of a
distinct kinase pathway composed of three sequential dual-specificity
kinases, generically termed the MAPKKK (MKKK or MEKK), MAPKK (MKK or
MEK), and MAPK. Following stimulation, the MKKK is dually
phosphorylated on specific residues by cellular signaling molecules.
This activated MKKK then phosphorylates the MKK. Once activated, the
MKK phosphorylates the MAPK on the appropriate threonine and tyrosine
residues, resulting in MAPK activation (10, 45).
Activated MAPKs can phosphorylate numerous substrates, including a
variety of transcription factors (2, 28, 52). In the case of
transcription factors, MAPK-mediated phosphorylation is a common
mechanism utilized by the cell to induce gene expression (28,
52). Largely through their ability to regulate transcription factors, MAPKs regulate changes in the cell ranging from cell growth to
apoptosis to senescence.
Because of the many effects of MAPK signaling on cell growth and
viability, the level of phosphorylated, and hence active, MAPK is
tightly regulated by the cell. Phosphorylation of MAPK is determined by
two processes, MKK kinase activity and phosphatase activity. In the
absence of stimulation, there is a low level of basal MKK kinase
activity, which phosphorylates the MAPK. This basal activity is
counteracted by an equal low level of basal MAPK phosphatase activity.
This balance prevents an accumulation of activated MAPK in the absence
of stimulation. Following stimulation, MAPK is dramatically activated
(by phosphorylation via the MAPK pathway). In many instances, shortly
after MAPK activation, MAPK phosphatases are activated. However, the
high levels of MKK activity prevents a decrease in the amount of
activated MAPK. Once the upstream signal subsides, MKK activity drops,
and the MAPK is quickly dephosphorylated by the activated phosphatases
(reviewed in reference 16).
Numerous viruses activate one or more of the MAPKs. For example, simian
virus 40 (SV40) activates ERK1/2, herpes simplex virus (HSV) activates
both JNK and p38, and simian immunodeficiency virus activates all three
MAPKs (34, 42, 54, 59). In addition, MAPK activation can be
induced by viral binding to the host cell, such as is the case with
simian immunodeficiency virus activation of ERK1/2, JNK, and p38, or it
can require viral protein synthesis, as is the case with HSV activation
of JNK (42).
While there are many reports which demonstrate MAPK activation
following viral infection, few have determined whether this activation
is important for a viral permissive infection. The recent
identification of dominant negative proteins and chemical compounds
which specifically inhibit different MAPK kinases have allowed more
detailed analysis of the function of MAPK activation in virally
infected cells (26, 27, 44). Using
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl) 1 H-imidazole
(FHPI), a drug which inhibits p38 kinase activity, investigators
demonstrated that p38 kinase activity was necessary for
interleukin-1-mediated increased in human immunodeficiency virus
replication (11), as measured by increases in pp24 levels (27, 48). In another study, dominant negative proteins were used to demonstrate that inhibition of HSV-mediated JNK activation significantly decreases viral titers (34). However, even
though p38 activation was observed following HSV infection, FHPI had no
effect on viral titers, indicating that not all MAPKs which are
activated following infection have a critical role in viral permissive
infection (T. I. McLean and S. L. Bachenheimer, personal communication).
Even in cases where it has been determined that MAPK activation has a
function in viral infection, little is known about how MAPK mediates
this effect. For example, MAPK substrates which are activated following
viral infection have not been identified. Furthermore, little is known
about cellular proteins that are involved in virus-mediated MAPK
activation. An understanding of these points is of great interest since
it will allow investigators to better examine the antiviral potential
of MAPKs, in addition to greatly increasing our knowledge of how the
virus regulates host cell machinery to ensure a permissive infection.
Interestingly, HCMV infection has been found to activate both ERK1/2
and p38. In the absence of prestimulation, ERK1/2 activation is
observed at 5 to 15 min following viral binding to the cell (3) and at 4 to 8 h postinfection (hpi) following viral
gene expression (46). Increased p38 activity is detected at
8 hpi and maintained through 48 hpi (19).
Excitingly, treatment of infected cells with drugs which inhibit either
ERK1/2 activation or p38 kinase activity significantly delays viral DNA
replication and subsequent plaque formation (19; R. A. Johnson, A. D. Yurochko, S.-M. Huong, and E.-S. Huang,
unpublished data). Additional studies have shown that inhibition of
either p38 or ERK1/2 kinase activity does not affect expression of the two viral major immediate-early (IE) genes, IE1-72 and IE2-86 (19,
46). However, while inhibition of ERK1/2 activation reduced expression of several viral E genes necessary for initiation of viral
DNA replication, inhibition of p38 kinase activity did not, suggesting
that rather than having redundant roles, each has a distinct function
in HCMV infection (19, 48; Johnson et al., unpublished data).
As with other viruses, little is known about the mechanism of p38
activation following HCMV infection or which cellular proteins are
phosphorylated in a p38-dependent manner following infection. Therefore, we have undertaken a detailed study into the mechanism of
p38 activation following HCMV infection. Initially, we provide evidence
that p38 is not activated immediately following viral binding to the
host cell. Rather, p38 is first activated at 8 to 10 hpi, and this
activation is maintained throughout infection (72 hpi), though a
decrease in activity is often detected at 24 hpi. Since extended
activation of p38 is unusual, we next examined whether any p38
substrates were also activated for extended periods of time in a
p38-dependent manner. We present data suggesting that activation of p38
for extended periods of time is necessary for HCMV-mediated
hyperphosphorylation of pRb, which is observed at 48 to 72 hpi, and for
phosphorylation of heat shock protein 27 (HSP27), which is observed
from 12 to 48 hpi.
We then focused on the mechanism by which HCMV-mediated this unusually
long-term activation of p38. We provide evidence that HCMV utilizes two
mechanisms to activate p38. Our results suggest that at early times of
infection, HCMV inhibits dephosphorylation of activated p38, allowing
an accumulation of phosphorylated p38 in the absence of increased
MKK3/6 activity. At later times of infection (48 to 72 hpi), increased
activation of MKK3/6 allows continued p38 activation. To our knowledge,
this is the first report of any stimulus or virus which activates p38
by inhibiting dephosphorylation, underscoring the complex interaction
between HCMV and infected host cells.
Collectively, the results of this study demonstrate that p38 is
activated for extended periods of time following infection, and they
also identify proteins phosphorylated in a p38-dependent manner in the
context of viral infection. Identifying these substrates is significant
since it will allow future investigation into the biological function
of p38 in HCMV infection. Finally, several lines of evidence presented
here suggest that HCMV has developed multiple mechanisms to ensure
activation of a cellular kinase which is critical to initiation of
viral DNA replication. Targeting these mechanisms may provide a means
to inhibit HCMV-mediated p38 activation and viral permissiveness.
 |
MATERIALS AND METHODS |
Cell culture and viral passage.
Human embryonic lung (HEL)
fibroblasts were cultured in Eagle's minimal essential media (EMEM)
(Gibco, BRL) supplemented with 10% fetal bovine serum (FBS) plus
antibiotics. The human astrocytoma cell line U373MG was grown in
Dulbecco's modified Eagle medium (DMEM) (Gibco, BRL) supplemented with
10% FBS plus antibiotics. Towne strain HCMV (passages 36 to 40) was
propagated in HEL fibroblasts as previously described (22).
Expression vectors and cell lines.
FLAG-pCDNA3-MKK3 dominant
negative (MKK3dn) and FLAG-pCDNA3-MKK6 dominant negative
(MKK6dn) expression vectors were kindly provided by Roger
Davis and have been previously described (44). To obtain
cell lines, U373 cells were seeded in 35-mm-diameter six-well plates at
106 cells/well. The following day they were transfected
with the indicated plasmid, using Fugene 6 as specified by the
manufacturer (Boehringer GmbH, Mannheim, Germany). Forty-eight hours
later, fresh DMEM containing 10% FBS, antibiotics, and G418 (800 µg/ml) was added to each well. The medium was changed every 5 days.
After G418 selection, the expression of transfected protein in U373 was
confirmed by Western blot analysis, immunoprecipitation, and immunofluorescence.
Antibodies and inhibitor drugs.
All phosphospecific
antibodies and the p38 nonphosphospecific antibody were purchased from
New England Biolabs (NEB; Beverly, Mass.). FLAG antibody M2 was
obtained from Kodak (Rochester, N.Y.). pRb antibody was from Santa Cruz
Biotechnology (Santa Cruz, Calif.), and cyclin D and cyclin E
antibodies were from Oncogene Science (Cambridge, Mass.). HSP27
antibody was from Sigma (St. Louis, Mo.). Anisomycin, rotenone, and
2-deoxyglucose were purchased from Sigma. The specific p38 inhibitor
drug FHPI was purchased from Calbiochem (La Jolla, Calif.).
Western blot analysis.
Fibroblasts were grown to confluence,
serum starved for 48 h, and then infected with HCMV at a
multiplicity of infection (MOI) of 2 to 5 PFU per cell as described
elsewhere (19). In experiments which utilized FHPI, cells
were pretreated with 10 µM FHPI for 1 h prior to infection.
Following pretreatment, cells were infected and incubated in the
presence of 10 µM FHPI as previously described (19). At
the indicated times, cells were harvested in 2× Laemmli sodium dodecyl
(SDS) sample buffer, boiled, and loaded onto SDS-polyacrylamide gels.
Mock-infected samples were treated and harvested in the same manner as
the infected samples, except that EMEM without virus was used during
the infection. Proteins were separated by polyacrylamide gel
electrophoresis (PAGE) and transferred overnight at 14 V to Immobilon-P
transfer membranes (Millipore, Bedford, Mass.). Blots were blocked for
30 min in 10% (wt/vol) Carnation nonfat dry milk dissolved in
phosphate-buffered saline (PBS) with 0.1% Tween 20 (PBS+T). Blots were
then probed with primary antibody (1:1,000 dilution) for 2 h at
room temperature or overnight at 4°C in PBS+T. Blots were washed
three times with PBS+T. After washing, the blots were probed with
secondary antibody (horseradish peroxidase-conjugated anti-mouse or
anti-rabbit immunoglobulin G [Sigma or NEB, respectively]). Blots
were washed in PBS+T and developed by enhanced chemiluminescence as
specified by the manufacturer (NEB).
Immunoprecipitations and kinase assays.
Glutathione
S-transferase (GST)-c-Jun (amino acids [aa] 1 to 79) and
GST-ATF-2 (full length) were purchased from NEB. p38 and JNK kinase
assays were performed as previously described (43). Briefly,
cells were pretreated and infected as described above. At the indicated
times, cells were harvested in lysis buffer (150 mM NaCl, 20 mM
Tris-HCl [pH 7.5], 1.0% Triton X-100, 0.5 mM EDTA, 50 mM NaF, 10%
glycerol, 20 µg of leupeptin per ml, 20 µg of phenylmethylsulfonyl fluoride [PMSF] per ml, 1 mM sodium vanadate
[Na3VO4]), rocked for 15 min at 4°C, and
then vortexed for 15 seconds. Cell debris was pelleted by
centrifugation, and the concentration of the supernatant was determined
by the Bio-Rad protein assay. For the JNK kinase assay, 75 µg of
supernatant was rocked for 4 h at 4°C with 1 µg of GST-c-Jun
bound to GST beads (Biochem Pharmacia). For the p38 assay, p38 was
immunoprecipitated overnight from 200 µg of supernatant in
ELB+ (0.25 M NaCl, 0.1% NP-40, 0.05 M HEPES [pH 7.0], 1 mM PMSF, 0.5 mM EDTA, 0.05 mM dithiothreitol [DTT]) plus 0.1 mM
Na3VO4 with a p38 polyclonal antibody and 15 µl of protein G-Sepharose beads (Biochem Pharmacia). After the
appropriate incubation, the beads were washed three times in lysis
buffer, and once in kinase buffer (20 mM HEPES [pH 7.5], 10 mM
MgCl2, 50 mM NaCl2, 5 mM
-glycerophosphate, 1.5 mM EGTA, 1 mM PMSF, 0.5 mM EDTA, 0.05 mM DTT, 0.1 mM
Na3VO4). Kinase assays were then performed,
using 5 µCi of [
-32P]ATP/reaction and, in the case
of p38, addition of 1 µg of GST-ATF-2. After a 20-min incubation at
30°C, the beads were washed once and then denatured with 2× SDS
sample buffer. After boiling, the samples were separated by SDS-PAGE on
a 12% polyacrylamide gel, dried, and subjected to autoradiography.
Bands were quantitated with a densitometer.
Heat treatment and ATP depletion.
Confluent, serum-starved
cells were washed once with EMEM which had been prewarmed to 45°C and
then incubated in EMEM at 45°C for 20 min. ATP depletion was
performed as previously described (35). Briefly, following
infection or heat treatment, cells were washed twice with PBS which was
preheated to 37°C. Cells were then incubated with PBS supplemented
with 5 µM rotenone and 10 mM 2-deoxyglucose at 37°C for the
indicated times. Following the appropriated incubation, cells were
washed twice with PBS and harvested in 2× SDS lysis buffer.
In vivo analysis of HSP27 phosphorylation.
Confluent,
serum-starved fibroblasts were infected as described above. Three hours
prior to harvesting, cells were washed twice with phosphate-free EMEM
prewarmed to 37°C and then incubated with 0.4 mCi of
[32P]orthophosphate per ml in phosphate-free EMEM (ICN).
Following a 3-h incubation, cells were harvested and protein
concentration was determined by the Bio-Rad protein assay as described
above. HSP27 was immunoprecipitated as described above and separated by
SDS-PAGE on a 12% gel. HSP27 phosphorylation was then determined by autoradiography.
 |
RESULTS |
Kinetics of p38 activation following viral infection.
Inhibition of p38 kinase activity by treatment of infected cells with
FHPI significantly inhibits HCMV DNA replication and decreases viral
titers (19). Determining the mechanism of HCMV-mediated p38
activation could identify new targets to inhibit this activation and,
therefore, viral permissiveness. Since little is known about p38
activation following HCMV infection, it was first necessary to
determine the kinetics of p38 activation during HCMV infection. With
this information, we could focus our investigation of the mechanism of
HCMV-mediated p38 activation on those times which correlated with
increased levels of p38 activity.
To determine the kinetics of activation, an extended time course was
performed. Confluent fibroblasts were serum starved for 48 h,
infected with HCMV at an MOI of 2 to 5 PFU, and harvested at the
indicated times postinfection. p38 activation was examined by Western
blot analysis using a phosphospecific antibody which recognizes only
the dually phosphorylated, and hence active, form of p38
(43). As shown in Fig. 1A, HEL
cells infected with HCMV did not display increased p38 activity from 10 to 40 min following infection (lanes 2 to 7). However, a strong
increase in p38 phosphorylation was detected by 10 hpi (Fig. 1B, lane
4), which is consistent with previously published reports
(19). p38 phosphorylation decreased between 14 and 24 hpi,
then increased dramatically between 24 and 48 hpi, and remained at this
level through 72 hpi (Fig. 4B, lanes 5 to 9). Western blot analysis
using an antibody which recognizes both phosphorylated and
nonphosphorylated p38 demonstrated that the overall levels of p38
protein were not significantly altered during the course of infection,
suggesting that the increase in phosphorylated p38 was not due to an
elevation in the amount of p38 analyzed (Fig. 1B, lower blot).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 1.
Activation of p38 following HCMV infection. HEL
fibroblasts were infected with sucrose gradient-purified virus at an
MOI of 2 to 5 PFU. Cells were then harvested in 2× SDS sample buffer
at the indicated time points, and Western blot analysis using a p38
phosphospecific antibody was performed. (A) Time course examining the
effect of HCMV infection on p38 activation at times corresponding to
the first tier of activation of host cell transcription factors. (B)
(Top) Western blot demonstrating that p38 is phosphorylated on
activating residues beginning at 10 hpi; (bottom) Western blot using
p38 antibody, which recognizes all forms of p38, demonstrating that the
overall levels of p38 do not fluctuate. (C) Viral protein synthesis is
necessary for HCMV-mediated p38 activation. Fibroblasts were infected
with unpurified virus stock at an MOI of 2 to 5 PFU. Where indicated,
virus was inactivated by UV irradiation prior to infection. Blots were
also probed for IE1-72 and IE2-86 gene expression to demonstrate
inactivation of virus by UV irradiation (UV-VIRUS). p.i.,
postinfection; (M), mock-infected cells; (I), infected cells; UV,
UV-irradiated HEL fibroblasts [positive control]); Phos.,
phosphorylated. The results are representative of five experiments.
|
|
To further characterize HCMV-mediated activation of p38, fibroblasts
were infected with unpurified virus stock which was either
untreated or
UV irradiated prior to infection. UV irradiation
creates thymidine
dimers which prevents transcription of viral
genes without inhibiting
the ability of the virus to bind to and
enter the host cell. As Fig.
1C
shows, p38 activation was observed
only following infection with live
virus, indicating that viral
protein synthesis is necessary for p38
activation following HCMV
infection. Similar results were obtained when
fibroblasts were
infected with sucrose gradient-purified live or
UV-irradiated
virus (data not
shown).
To verify that p38 phosphorylation correlated with p38 kinase activity,
a p38 kinase immunocomplex assay was performed with
GST-ATF-2 as a
substrate. As shown in Fig.
2,
quantitation of
band intensity demonstrates that p38 kinase activity
correlated
well with p38 phosphorylation (compare Fig.
1B with Fig.
2),
in
which activation was observed at early times of infection, decreased
at 24 hpi, and then rose again at 48 hpi. The drop in p38 activation
at
24 hpi, which was found in most, though not all, time courses,
suggested that p38 activation may be biphasic.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 2.
HCMV-induced p38 phosphorylation correlates with
increases in p38 kinase activity. Fibroblasts were treated and infected
as for Fig. 1. At the indicated time points, cells were harvested in
lysis buffer, and p38 kinase activity was determined by using
GST-ATF-2 (aa 1 to 254) as a substrate. Autoradiography was analyzed
with a densitometer, and the quantitation is shown. (M), mock infected.
The data are representative of two separate experiments.
|
|
The results in Fig.
1 and
2 demonstrate that p38 is activated for an
extended period of time following HCMV infection. It
is very unusual
for stimuli to induce such a prolonged activation
of p38, and the fact
that HCMV does supports our hypothesis that
p38 activation has a very
important role in HCMV infection for
extended periods of
time.
HCMV infection results in hyperphosphorylation of pRb and
phosphorylation of HSP27 in a p38-dependent manner.
The results in
Fig. 1 and 2 suggest that p38 has a role in HCMV infection throughout
the course of infection. However, no one has yet examined if the
extended activation of p38 correlates with activation of any p38
substrates in the context of viral infection. For this reason, we
sought to identify substrates which are phosphorylated in a
p38-dependent manner following viral infection. Following activation by
certain stimuli, p38 phosphorylates the pocket protein pRb and HSP27
(13, 47, 50). Furthermore, under specific conditions,
increased p38 kinase activity can regulate expression of the cell
cycle-regulating protein cyclin D (25).
We therefore examined whether under our conditions HCMV infection can
induce hyperphosphorylation of pRb and whether inhibiting
p38 kinase
activity affected pRb phosphorylation following infection.
Fibroblasts
were infected in the presence or absence of FHPI,
a drug that
specifically inhibits of p38 kinase activity and that
we have
previously used to examined the role of p38 in HCMV infection
(
19,
27). We then examined by Western blot analysis the level
of pRb
hyperphosphorylation at various times following infection.
As shown in
Fig.
3A, HCMV induced pRb
hyperphosphorylation by
48 hpi (lane 4). In the presence of FHPI, the
amount of hyperphosphorylated
pRb was significantly less (lane 5). This
finding indicates that
p38 kinase activity effects pRb phosphorylation
following viral
infection.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 3.
Inhibition of p38 kinase activity inhibits HCMV-mediated
pRb hyperphosphorylation but does not effect HCMV mediated changes in
cyclin E or cyclin D protein levels. Fibroblasts were grown to
confluence and then serum starved for 48 h. Cells were pretreated
for 1 h with 10 µM FHPI prior to infection with HCMV. HCMV
infection was done in the presence of FHPI, and extracts were harvested
at the indicated times. Western blot analysis was performed with
antibody for pRb (A), cyclin D (B), and cyclin E (C). M, mock infected;
Phos., phosphorylated. Each experiment was performed at least three
times, and representative blots are shown.
|
|
We next examined if treatment of FHPI altered cyclin D and, as a
control, cyclin E, protein levels in HCMV-infected cells.
HEL cells
were infected in the presence or absence of FHPI, and
the levels of
cyclin D and cyclin E proteins were determined at
the indicated times
of infection by Western blot analysis. As
previously reported, we found
that cyclin D levels began to drop
at 24 to 28 hpi (Fig.
3B, lanes 5 and 7) (
5). As was also previously
demonstrated, cyclin E
protein levels increased slightly at 24
to 48 h (Fig.
3C, lanes 2 and 4) and then decreased at 48 to 72
hpi (lanes 6 and 8)
(
5). In both cases, FHPI had no effect
on HCMV-mediated
changes in protein levels. This indicates that
following HCMV
infection, p38 activity does not have a role in
regulating cyclin D or
cyclin E protein
levels.
Finally, we examined the ability of p38 to regulate phosphorylation of
HSP27 following viral infection. HEL cells were infected
in the
presence or absence of FHPI and then labeled with
[
32P]orthophosphate for 3 h prior to harvesting.
HSP27 was immunoprecipitated
from whole cell extract and separated by
SDS-PAGE, and the amount
of phosphorylated HSP27 was determined by
autoradiography. As
shown in Fig.
4,
HSP27 was strongly phosphorylated at early (12
hpi) and late (48 hpi)
times of infection, and this increase in
phosphorylation was blocked by
the presence of the p38 inhibitor
compound FHPI (Fig.
4; compare lanes
2 and 4 with lanes 3 and
5).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 4.
p38 kinase activity is necessary for phosphorylation of
HSP27 following viral infection. Confluent, serum-starved fibroblasts
were infected and then labeled with 0.4 mCi of
[32P]orthophosphate per ml in the presence or absence of
FHPI 3 h prior to being harvested. At the indicated times, cell
extracts were harvested, and HSP27 was immunoprecipitated from 500 µg
of whole-cell extract per sample, separated by SDS-PAGE on a 12% gel,
and subjected to autoradiography. M, mock infected; Phos.,
phosphorylated.
|
|
These data indicate that activated p38 regulates phosphorylation of
specific substrates throughout the course of infection.
As discussed
below, these results also identify biological mechanism
by which p38
may affect HCMV viral DNA
replication.
HCMV infection does not activate MKK4 or JNK.
The above
results confirm that p38 has an active role in phosphorylating specific
substrates for extended periods of time following infection. Since
extended activation of p38 is unusual, we were interested in how HCMV
was able to maintain p38 activation. This would further our
understanding of the interaction between HCMV and the host cell, with
the long-term view of identifying novel targets to inhibit
HCMV-mediated p38 activation and, subsequently, viral permissive infection.
Following exposure to stimuli, increases in the level of phosphorylated
p38 are due to increased phosphorylation or kinase
activity of MKK3/6
and/or MKK4 (reviewed in references
10 and
38). Based on this knowledge, we first examined if
MKK4 was
activated following infection. Again, we used a
phosphospecific
antibody, in this case one which recognizes only
phosphorylated,
and hence activated, MKK4. Having determined the
kinetics of p38
activation (Fig.
1), we could focus on times of
infection which
corresponded to p38 activation. As shown in Fig.
5A, HCMV infection
did not activate MKK4
(lanes 2 to 6), while treatment of HEL fibroblasts
with anisomycin (a
strong MKK4 activator) strongly induced MKK4
phosphorylation (lane 5).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
HCMV infection does not activate MKK4 or JNK. (A)
Western blot analysis of infected whole-cell extract with an antibody
which recognizes only active MKK4. For the positive control, HEL
fibroblasts were treated with anisomycin (10 µg/ml) for 20 min and
harvested in the same manner as the HCMV-infected cells. (B) JNK is not
activated following HCMV infection. Cells were infected with HCMV and
harvested in JNK lysis buffer, and JNK kinase activity was determined
with GST-c-Jun (aa 1 to 79) as a substrate. Following autoradiography,
band intensity was determined with a densitometer, and the quantitated
results are shown. UV-irradiated fibroblasts were used as a positive
control. (M), mock infected; Phos., phosphorylated. Each panel shows
representative data from at least three separate experiments.
|
|
To further demonstrate that MKK4 was not activated following HCMV
infection, we examined the effect of HCMV infection on activation
of a
second MKK4 substrate, JNK (
9,
29,
38). A JNK kinase
assay
was performed with GST-c-Jun as a substrate. Quantitation
of band
intensity (Fig.
5B) demonstrates that JNK activity does
not increase
significantly following HCMV infection. Together,
these data indicate
that MKK4 kinase activity is not increased
during HCMV infection and
therefore cannot account for the increases
in p38
activation.
MKK3 and MKK6 are activated at late times of HCMV infection.
Next, we determined if viral infection activated MKK3 and MKK6, the
remaining two cellular kinases which are known to phosphorylate p38
(10). Interestingly, while we observed a strong increase in
MKK3/6 phosphorylation at 48 and 72 hpi (Fig.
6A, lanes 5 and 6), only a very slight
increase in phosphorylation was observed at 12 hpi (lanes 2 and 3).
Again, Western blot analysis for
-actin demonstrated that equal
amounts of protein were loaded in each lane (Fig. 6B). Thus, increased
MKK3/6 activity accounts for p38 activation at later times of infection
(48 to 72 hpi). Since HCMV infection results in the activation of p38
as early as 8 hpi, we postulated that there must exist another
mechanism to account for the strong activation of p38 at the earlier
time points.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 6.
HCMV infection strongly activates MKK3/6 at later times
of infection. (A) Fibroblast extract used in Fig. 5 were probed for
MKK3/6 activation using an MKK3/6 phosphospecific antibody. Band
intensity was quantitated with a densitometer. (B) Western blot
analysis for -actin demonstrates equal protein loading in all
samples. (M), mock infected; Phos., phosphorylated. The data shown are
representative of results from four separate experiments.
|
|
Basal kinase activity of MKK3/6 is needed for p38 phosphorylation
at early times of infection.
In response to heat shock, JNK is
activated through inhibition of dephosphorylation rather than increased
activity of upstream kinases (35). This activation requires
basal upstream kinase activity (in the case of JNK, basal MKK4 activity
is required) and inhibition of dephosphorylation of activated JNK. We
were interested in determining whether HCMV activated p38 in a similar mechanism, since we were unable to detect an increase in MKK activity at early times postinfection. To test this theory, it was first necessary to demonstrate that basal activity of an MKK is necessary for
p38 activation following HCMV infection. Since there are no drugs
available to inhibit MKK3/6 kinase activity, we made cell lines which
expressed a nonphosphorylated MKK6 or MKK3 (MKK3dn and
MKK6dn). These are dominant negative proteins which have
their phosphorylation sites mutated, and when overexpressed, they
prevent the wild-type protein from becoming phosphorylated
(44).
Due to their low transfectability and ability to be passaged only a
limited number of times in tissue culture, HEL fibroblasts
are
unsuitable for making stable expressing cell lines by transient
transfection assay. Therefore, MKK3
dn-,
MKK6
dn-, and vector control (pCDNA3)-expressing cell lines
were made
in the U373MG cells, which like fibroblasts are fully
permissive
for HCMV infection in tissue culture. Importantly, the
pattern
of p38 and MKK3/6 activation in U373MG cells following HCMV
infection
mirrors that in infected fibroblasts (data not shown). After
transfection
and subsequent selection, protein expression in the cell
lines
was confirmed by immunofluorescence, immunoprecipitation, and
Western blot analysis (Fig.
7A and data
not shown). Following
establishment of the cell lines, the cells were
infected, harvested,
and analyzed for phosphorylation of p38 by Western
blot analysis.
As shown in Fig.
7B, expression of MKK6
dn
strongly inhibited the ability of HCMV infection to induce p38
phosphorylation at 12 hpi (compare lanes 4 and 6), while
MKK3
dn had a much less significant effect on virus-mediated
p38 activation
(compare lanes 4 and 5). This finding suggests that
kinase activity
of MKK6 is necessary for HCMV to induce p38
phosphorylation at
early times of infection, even though only a slight
increase in
MKK6 phosphorylation is observed at this time of infection
(Fig.
6).

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 7.
Basal levels of MKK3/6 kinase activity are necessary and
sufficient for HCMV-mediated p38 activation. U373 cells were
transfected with an expression vector for either MKK3dn or
MKK6dn. (A) After selection in medium containing G418 (800 µg/ml), Western blot analysis using a FLAG monoclonal antibody was
performed to verify protein expression. (B) Cells were pretreated,
infected, and harvested as for Fig. 1. Western blot analysis was
performed with polyclonal phosphospecific (to demonstrate p38
activation) or nonphosphospecific (to demonstrate that overall levels
of p38 were equal) p38 antibodies. Phos., phosphorylated. The data are
representative of results from three separate experiments.
|
|
HCMV inhibits dephosphorylation of p38 at early but not late times
of infection.
The results in Fig. 7 suggest that p38 is activated
by the low levels of MKK6 basal kinase activity that is present in
unstimulated cells. For this basal kinase activity to increase the
steady-state level of phosphorylated p38, dephosphorylation of active
p38 needs to be inhibited. This would allow a buildup of activated p38. Therefore, the next step was to determine the effect of HCMV infection on dephosphorylation of active p38. Traditional pulse-chase assays are
not sensitive enough for examining the inhibition of dephosphorylation under these experimental conditions (35). Therefore, to
assess the effect of HCMV infection on dephosphorylation of p38, it was necessary to inhibit the ability of upstream kinases (such as MKK3 and
MKK6) to phosphorylate p38 and then monitor the rate of decline in the
levels of phosphorylated p38. To accomplish this task, we used the
technique of ATP depletion, which was successfully used by Meriin et
al. to examine the rate of dephosphorylation of p38 and JNK following
various stress treatments (35). In this experiment, cells
are treated with the indicated stress. ATP is then depleted from the
cells, which inhibits upstream kinase activity. This prevents the cell
from further phosphorylating p38, and therefore the rate of
dephosphorylation is the sole determinant of the level of
phosphorylated p38. Following ATP depletion, time points are taken, and
the amount of phosphorylated protein is determined by Western blot
analysis with phosphospecific antibodies. Meriine et al. also
demonstrated that heat shock-mediated p38 activation was not mediated
through inhibition of dephosphorylation (35). Therefore, we
used heat shock treatment as our control for the rate of dephosphorylation.
Cells were either infected for 12 h or heat shocked for 20 min and
then subjected to ATP depletion. Cell extracts were harvested
at 0, 10, 15, and 20 min following addition of ATP-depleting reagents.
Subsequent
Western blot analysis demonstrated that the amount
of phosphorylated
p38 decreased significantly in heat-shocked
cells between 10 and 15 min
after addition of ATP-depleting reagents
(Fig.
8A, compare lanes 7 and 8). This
indicated that if phosphatase
activity is not inhibited, a decrease in
the amount of phosphorylated
p38 should be observed between 10 and 15 min after addition of
ATP-depleting reagents. When cells infected for
12 h with HCMV
were subjected to ATP depletion, only a slight drop
in the amount
of phosphorylated p38 was detected between 10 and 15 min
after
addition of ATP-depleting reagents (compare lanes 3 and 4). This
indicates that HCMV infection is able to inhibit dephosphorylation
of
active p38. To our knowledge, this is the first report of p38
activation via inhibition of dephosphorylation of p38 by any stimulus.

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 8.
HCMV infection inhibits dephosphorylation of active p38
at early, but not late, times of infection. (A) U373 cells were
infected for 12 h or subjected to heat shock (45°C for 20 min).
ATP was depleted by the addition of rotenone and 2-deoxyglucose, and
cells were harvested at the indicated times after depletion. The amount
of phosphorylated p38 was determined by Western blot analysis. (B)
Cells were infected for 48 h and then subjected to ATP depletion
and Western blot analysis as for panel A. Time 0, start of ATP
depletion; M, mock-infected cells; Phos., phosphorylated.
|
|
We next examined whether dephosphorylation of activated p38 was also
inhibited at later times of infection, when phosphorylation
of both p38
and MKK3/6 is observed. To answer this question, ATP
depletion was
performed on cells which had been infected for 48
h. As shown in
Fig.
8B, following addition of ATP-depleting reagents,
dephosphorylation of activated p38 occurred extremely rapidly.
No
phosphorylated p38 could be detected by 10 min after the start
of ATP
depletion. This finding indicates that at 48 hpi, HCMV
can no longer
inhibit dephosphorylation of active p38. Based on
this observation, we
have developed a model in which HCMV utilizes
two mechanisms to ensure
activation of p38 for extended periods
of time (Fig.
9). At early times of HCMV infection,
dephosphorylation
of active p38 is inhibited, resulting in an
accumulation of activated
p38 (Fig.
9A). In contrast, at later times of
infection, the ability
of HCMV to inhibit p38 dephosphorylation is
lost, indicating another
mechanism is responsible for p38 activation.
This mechanism is
likely the significant increase in MKK3/6 activity
that we observed
at 48 to 72 hpi (Fig.
6 and
9B). It is important to
remember that
in the ATP depletion experiment, MKK3/6 cannot
phosphorylate p38
(since no ATP is present), and therefore MKK3/6 is
unable to maintain
phosphorylation of p38. However, in the presence of
ATP, the increased
MKK3/6 activity is sufficient to activate p38.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 9.
Model for HCMV-mediated p38 activation. (A) At early
times of infection, when no increase in MKK3/6 or MKK4 kinase activity
is observed, the virus prevents phosphatases from recognizing activated
p38. As basal MKK3/6 kinase activity continues to phosphorylate p38,
phosphatases are unable to dephosphorylate p38, and so the amount of
activated p38 accumulates. (B) At later times of infection, MKK3/6
kinase activity is increased, resulting in p38 activation.
|
|
Again, the findings presented here underscore the importance of p38
activation in viral infection. The virus has developed
two mechanisms
to ensure activation of p38. These findings are
exciting because the
unusual mechanism of p38 activation at 12
hpi may provide an antiviral
target which inhibits HCMV-mediated
p38 activation without affecting
p38 activation in response to
other
stimuli.
 |
DISCUSSION |
In vivo, primary targets for HCMV lytic infection are terminally
differentiated cells in which many macromolecules and cellular pathways, including kinase pathways such as p38, which HCMV needs to
undergo a lytic infection, are present at low levels or are inactive
(53). Several recent studies have shown that HCMV infection elicits a mitogenic-like response which results in activation of these
critical cellular components (see the introduction). However, little is
known about the mechanism by which HCMV induces this activation. In
this report, we have examined the kinetics and mechanisms of p38
activation following HCMV infection. In fibroblasts, viral protein
expression is necessary to obtain p38 activation, which is first
observed at 8 to 10 hpi (Fig. 1 and 2). This is somewhat surprising,
since our laboratory recently reported that HCMV infection of monocytes
results in a dramatic up regulation of p38 kinase activity by 15 min
postinfection, independent of viral protein expression (55).
One explanation for these differences is that HCMV may utilize
different receptors to bind fibroblasts and monocytes. Alternatively,
HCMV infection may regulate p38 activation differently in permissive
cell types (such as fibroblasts) compared to nonpermissive cell types
(such as monocytes). Currently, we are trying to address this issue by
first identifying HCMV receptors on monocytes and fibroblasts. In
addition, we are comparing activation of p38 following HCMV infection
of other permissive and nonpermissive cell types.
We were also unable to detect p38 activation following infection of
unpurified viral stock in which HCMV had been inactivated by UV
irradiation prior to infection (Fig. 1C). This suggests that secreted
cytokines released by infected cells into the media are not responsible
for p38 activation in this case. Based on these results, we believe it
most likely that viral proteins themselves are responsible for p38
activation throughout the course of infection.
We then provide evidence that HCMV infection induces
hyperphosphorylation of pRb and HSP27 in a p38-dependent manner. These results not only demonstrate that p38 is functionally active throughout infection but also provide insight into how p38 may mediate its biological effects on viral DNA replication. pRb regulates expression of many cellular proteins associated with DNA synthesis, and many of
these proteins are thought to be necessary for viral DNA replication (51). At early stages of the cell cycle, pRb is
hypophosphorylated, and in this form it acts as an inhibitor of gene
expression, in most instances by directly complexing with transcription
factors such as E2F and suppressing their transactivation function
(51). Upon exposure to a proliferative signal, the cell
induces hyperphosphorylation of pRb. Once hyperphosphorylated, pRb
loses its ability to suppress transactivation function, which results
in transcription of the genes necessary for progression into S phase
and subsequent cellular DNA synthesis.
The classical binding partner for pRb is the E2F family of
transcription factors, and hyperphosphorylation of pRb is necessary for
relieving pRb-mediated suppression of E2F, which results in cell cycle
progression past the G1/S phase transition point (reviewed in reference 39). However, the HCMV IE2-86 protein
binds to pRb and alleviates pRb-mediated suppression of E2F
transactivation function (15). Furthermore, IE2-86 has a
high affinity for hypophosphorylated pRb, suggesting that HCMV can
induce E2F transactivation function in the absence of pRb
hyperphosphorylation (15). Therefore, while FHPI inhibits
the pRb hyperphosphorylation observed following HCMV infection, it is
likely that it does not inhibit pRb-mediated suppression of E2F
transactivation function in the context of viral infection. Indeed, our
preliminary results indicate this is the case (data not shown).
However, pRb also regulates the activity of several other proteins in a
phosphorylation-dependent manner. As with E2F, these proteins, which
include histone deacetylases and RNA polymerase III, regulate
expression of a variety of cellular genes involved in cell cycle
progression and likely have important functions in viral infection
(4, 24, 25, 32, 33). Currently, we are investigating the
role of these other proteins in viral infection.
HSP27 appears to have a critical role in protecting cells from
apoptosis following certain stresses (reviewed in references 8 and 14). One mechanism by which
it does this is by acting as a molecular chaperone. It binds to
proteins and can either prevent their incorrect folding or association
with inhibitory proteins and/or ensure their translocation between
subcellular compartments (14). In the context of viral
infection, p38-mediated activation of HSP27 could have two functions.
It might serve to inhibit apoptosis following external stresses. This
would ensure that the virus is able to complete its life cycle before
the cell dies. Alternatively, infection itself is a type of stress and may cause inactivation of proteins which are necessary for viral permissiveness, due to either misfolding or incorrect compartmental localization. Therefore, HCMV may activate HSP27 to ensure that these
proteins are active and able to perform their function as it relates to
HCMV-permissive infection. As with the pRb hyperphosphorylation, we are
currently addressing these possibilities.
The next series of experiments characterized the mechanism of
HCMV-mediated p38 activation. Using ATP depletion, we provided evidence
that at early times of infection, HCMV inhibited dephosphorylation of
activated p38, allowing an increase in the steady-state levels of
phosphorylated p38 in the presence of only basal MKK6 kinase activity.
We also consistently detected an increase in the amount of active p38
immediately following addition of ATP-depleting reagents but before ATP
had been depleted from the cells (Fig. 8, compare lanes 2 and 3). This
increase was not due to the process of ATP depletion, as no increase in
the amount of phosphorylated p38 was detected following addition of
ATP-depleting reagents to either heat-shocked cells or cells infected
with HCMV for 48 h. Little is known about the mechanism which
mediates activation of p38 or JNK by inhibition of dephosphorylation,
and therefore it is difficult to speculate on why this increase occurs.
It may be due to the efficient use of residual ATP by HCMV-infected
cells before the ATP depletion is complete. Alternatively, it may be a
characteristic of stimuli which activates p38 or JNK by inhibition of
dephosphorylation. We are currently addressing these questions experimentally.
While inhibition of dephosphorylation is an uncommon mechanism for
inducing MAPK activation, a similar mechanism was recently found for
heat shock-mediated activation of JNK (35). In that study,
basal MKK4 kinase activity coupled with inhibition of JNK dephosphorylation was sufficient to induce JNK activation. Two other
reports have been published, both examining activation of ERK1/2 by
inhibition of dephosphorylation. The first report described inhibition
of protein phosphatase PP2A activity by SV40 small T antigen
(41). This inhibition allowed accumulation of phosphorylated MKK1/2 and ERK in the absence of increased MKKK activity
(54). A second report demonstrated that activation of ERK1/2
following HCMV infection of prestimulated fibroblasts may be at least
partially due to inhibition of ERK1/2 dephosphorylation
(46).
It may be fortuitous for HCMV to use an unusual mechanism to activate
p38. For instance, increased MKK6 kinase activity has been implicated
in some types of apoptosis (18). By not increasing MKK6
kinase activity, HCMV may avoid this effect, which would be detrimental
to a successful viral life cycle. Also, many stimuli that activate p38
by activation of upstream kinases also activate JNK. Recently, it has
been suggested that the antiviral property of tumor necrosis factor
alpha may be due to its ability to activate JNK (1). By
activating p38 through inhibition of dephosphorylation rather than
increasing kinase activity of MKKs, perhaps HCMV ensures that JNK is
not activated. This theory is supported by our findings that neither
MKK4 nor JNK is activated following infection (Fig. 5).
HCMV could inhibit dephosphorylation of activated p38 by two
mechanisms. It could directly bind to and inactivate one or more p38-specific phosphatases. This would be analogous to SV40 small T
antigen, which binds to a subunit of the PP2A complex, preventing the
formation of an active PP2A (41, 54). Alternatively, it could somehow prevent active phosphatases from recognizing p38, perhaps
by binding p38 in such a way that it is masked from the phosphatases.
We have found that p38 phosphatases are strongly activated following
infection (data not shown), which correlates with previously published
data showing that PP2A and PP1, both of which can dephosphorylate p38,
are activated following HCMV infection (36). These findings
suggest that p38 is likely activated by the latter mechanism (activated
phosphatases cannot recognize phosphorylated p38) following HCMV infection.
Currently, we are addressing the question of which viral proteins are
responsible for the inhibition of dephosphorylation. One problem with
identifying these candidates is that it is difficult to determine the
exact time at which the infected cell begins accumulating
phosphorylated p38. The earliest we have been able to detect p38
phosphorylation is 6 to 8 hpi. However, since activation depends on
basal kinase activity, it may be quite some time between the
commencement of inhibition of p38 dephosphorylation and the detection
of p38 activation. We have looked for the ability of the two major
viral IE proteins (IE1-72 and IE2-86) to activate p38 but have been
unable to induce p38 activation by overexpression of either IE2-86 or
IE1-72 (data not shown). Aside from the possibility that these proteins
may not be involved in p38 activation, two alternate explanations for
why we have been unable to detect p38 activation by specific viral
proteins are that posttranslational modification of IE proteins, such
as phosphorylation, and/or expression of multiple viral genes is
necessary to obtain p38 activation. Our search has been further
complicated by the fact that different mechanisms are utilized to
activate p38 at early and late times of infection. Currently, we are
developing better techniques to identify the viral proteins necessary
for p38 activation.
We went on to show that at later times of infection, HCMV no longer
inhibited dephosphorylation of activated p38 (Fig. 8B). However, MKK3/6
activity was increased at these later times of infection (Fig. 6), and
this increased activity was sufficient to increase the steady-state
level of activated p38. This finding indicates HCMV utilized a
different mechanism to activate p38 at later times of infection. These
results may also explain why a decrease in p38 phosphorylation was
often observed at 24 hpi. The ability of HCMV to inhibit
dephosphorylation of p38 may be lost before MKK3/6 is activated. At
that time of infection, no mechanism to activate p38 would be present,
and the levels of phosphorylated p38 would drop.
This characterization of HCMV-mediated p38 activation provides
important new insight into the complex interaction between HCMV and the
infected host cell. We have demonstrated that p38 is activated during
viral infection. We have also identified two p38 substrates which are
phosphorylated in a p38-dependent manner in the context of a viral
infection, which will be helpful in future studies of the biology of
p38 function in the context of viral infection. Finally, this study
provides strong evidence that HCMV activates p38 by two different
mechanisms, including the very unusual mechanism of inhibition of
dephosphorylation. Since it is unusual, it may provide a future target
for preventing p38 activation and, subsequently, HCMV infection.
 |
ACKNOWLEDGMENTS |
We are grateful to R. J. Davis for providing the
MKK3dn and MKK6dn expression vectors. We also
thank Xuli Ma for technical assistance and M. Hiremath, A. Yurochko, M. Mayo, and R.-H.E.S. Bitter for critical reviews of the manuscript.
R.A.J. is a virology training grant (2T32 AI07419) recipient. This work
was supported by grants AI12717 and CA19014 from the National
Institutes of Health (to E.-S.H.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: 32-026 Lineberger Comprehensive Cancer Center, CB# 7295, University of North
Carolina, Chapel Hill, NC 27599-7295. Phone: (919) 966-4323. Fax: (919) 966-4303. E-mail: eshuang{at}med.unc.edu.
 |
REFERENCES |
| 1.
|
Allan-Yorke, J.,
M. Record,
C. de Preval,
C. Davrinche, and J. L. Davignon.
1998.
Distinct pathways for tumor necrosis factor alpha and ceramides in human cytomegalovirus infection.
J. Virol.
72:2316-2322[Abstract/Free Full Text].
|
| 2.
|
Andrisani, O. M.
1999.
CREB-mediated transcriptional control.
Crit. Rev. Eukaryotic Gene Expr.
9:19-32[Medline].
|
| 3.
|
Boyle, K. A.,
R. L. Pietropaolo, and T. Compton.
1999.
Engagement of the cellular receptor for glycoprotein B of human cytomegalovirus activates the interferon-responsive pathway.
Mol. Cell. Biol.
19:3607-3613[Abstract/Free Full Text].
|
| 4.
|
Brehm, A.,
E. A. Miska,
D. J. McCance,
J. L. Reid,
A. J. Bannister, and T. Kouzarides.
1998.
Retinoblastoma protein recruits histone deacetylase to repress transcription.
Nature (London)
391:597-601[CrossRef][Medline].
|
| 5.
|
Bresnahan, W. A.,
I. Boldogh,
E. A. Thompson, and T. Albrecht.
1996.
Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1.
Virology
224:150-160[CrossRef][Medline].
|
| 6.
|
Britt, W. J., and C. A. Alford.
1996.
Cytomegalovirus, 3rd ed., vol. 2.
Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 7.
|
Chau, N. H.,
C. D. Vanson, and J. A. Kerry.
1999.
Transcriptional regulation of the human cytomegalovirus US11 early gene.
J. Virol.
73:863-870[Abstract/Free Full Text].
|
| 8.
|
Ciocca, D. R.,
S. Oesterreich,
G. C. Chamness,
W. L. McGuire, and S. A. Fuqua.
1993.
Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review.
J. Natl. Cancer Inst.
85:1558-1570[Abstract/Free Full Text].
|
| 9.
|
Derijard, B.,
J. Raingeaud,
T. Barrett,
I. H. Wu,
R. J. Ulevitch, and R. J. Davis.
1995.
Independent human MAPK kinase signal transduction pathways defined by MEK and MKK isoforms.
Science
267:682-685[Abstract/Free Full Text].
|
| 10.
|
Dhanasekaran, N., and E. P. Reddy.
1998.
Signaling by dual specificity kinases.
Oncogene
17:1447-1455[CrossRef][Medline].
|
| 11.
|
Favata, M. F.,
K. Y. Horiuchi,
E. J. Manos,
A. J. Daulerio,
D. A. Stradley,
W. S. Feeser,
D. E. Van Dyk,
W. J. Pitts,
R. A. Earl,
F. Hobbs,
R. A. Copeland,
R. L. Magolda,
P. A. Scherle, and J. M. Trzaskos.
1998.
Identification of a novel inhibitor of mitogen-activated protein kinase kinase.
J. Biol. Chem.
273:18623-18632[Abstract/Free Full Text].
|
| 12.
|
Field, A. K., and K. K. Biron.
1995.
"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.
Clin. Microbiol. Rev.
7:1-13[Abstract/Free Full Text].
|
| 13.
|
Freshney, N. W.,
L. Rawlinson,
F. Guesdon,
E. Jones,
S. Cowley,
J. Hsuan, and J. Saklatvala.
1994.
Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27.
Cell
78:1039-1049[CrossRef][Medline].
|
| 14.
|
Georgopoulos, C., and W. J. Welch.
1993.
Role of the major heat shock proteins as molecular chaperones.
Cell Biol.
9:601-634.
|
| 15.
|
Hagemeier, C.,
R. Caswell,
G. Hayhurst,
J. H. Sinclair, and T. Kouzarides.
1994.
Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein.
EMBO J.
13:2897-2903[Medline].
|
| 16.
|
Haneda, M.,
T. Sugimoto, and R. Kikkawa.
1999.
Mitogen-activated protein kinase phosphatase: a negative regulator of the mitogen-activated protein kinase cascade.
Eur. J. Pharmacol.
15:1-7[CrossRef].
|
| 17.
|
Huang, E.-S., and T. F. Kowalik.
1993.
The pathogenicity of human cytomegalovirus: an overview, p. 1-45.
In
Y. Becker, G. Darai, and E. S. Huang (ed.), Molecular aspects of human cytomegalovirus diseases. Springer-Verlag, Berlin, Germany.
|
| 18.
|
Huang, S.,
Y. Jiang,
Z. Li,
E. Nishida,
P. Mathias,
S. Lin,
R. J. Ulevitch,
G. R. Nemerow, and J. Han.
1997.
Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAPK kinase kinase 6b.
Immunity
6:739-749[CrossRef][Medline].
|
| 19.
|
Johnson, R. A.,
S. Huong, and E. Huang.
1999.
Inhibitory effect of 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1 H-imidazole on HCMV DNA replication and permissive infection.
Antiviral Res.
41:101-111[CrossRef][Medline].
|
| 20.
|
Kerry, J. A.,
M. A. Priddy,
T. L. Staley,
T. R. Jones, and R. M. Stenberg.
1997.
The role of ATF in regulating the human cytomegalovirus DNA polymerase (UL54) promoter during viral infection.
J. Virol.
71:2120-2126[Abstract].
|
| 21.
|
Kerry, J. A.,
M. A. Priddy, and R. M. Stenberg.
1994.
Identification of sequence elements in the human cytomegalovirus DNA polymerase gene promoter required for activation by viral gene products.
J. Virol.
68:4167-4176[Abstract/Free Full Text].
|
| 22.
|
Kowalik, T. F.,
B. Wing,
J. S. Haskill,
J. C. Azizkhan,
A. S. Baldwin, Jr., and E.-S. Huang.
1993.
Multiple mechanisms are implicated in the regulation of NF- B activity during human cytomegalovirus infection.
Proc. Natl. Acad. Sci. USA
90:1107-1111[Abstract/Free Full Text].
|
| 23.
|
Larminie, C. G.,
H. M. Alzuherri,
C. A. Cairns,
A. McLees, and R. J. White.
1998.
Transcription by RNA polymerases I and III: a potential link between cell growth, protein synthesis and the retinoblastoma protein.
J. Mol. Med.
76:94-103[CrossRef][Medline].
|
| 24.
|
Larminie, C. G.,
C. A. Cairns,
R. Mital,
T. Kouzarides,
S. P. Jackson, and R. J. White.
1997.
Mechanistic analysis of RNA polymerase III regulation by the retinoblastoma protein.
EMBO J.
16:2061-2071[CrossRef][Medline].
|
| 25.
|
Lavoie, J. N.,
G. L'Allemain,
A. Brunet,
R. Muller, and J. Pouyssegur.
1996.
Cyclin D1 expression is regulated positively by the p42/p44MAPK pathway.
J. Biol. Chem.
271:20608-20616[Abstract/Free Full Text].
|
| 26.
|
Lee, J. C., and J. L. Adams.
1995.
Inhibitors of serine/threonine kinases.
Curr. Opin. Biotechnol.
6:657-661[CrossRef][Medline].
|
| 27.
|
Lee, J. C.,
J. T. Laydon,
P. C. McDonnell,
T. F. Gallagher,
S. Kumar,
D. Green,
D. McNulty,
M. J. Blumenthal,
J. R. Heys,
S. W. Landvatter,
J. E. Strickler,
M. M. McLaughlin,
I. R. Siemens,
S. M. Fisher,
G. P. Livi,
J. R. White,
J. L. Adams, and P. R. Young.
1994.
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis.
Nature (London)
372:739-746[CrossRef][Medline].
|
| 28.
|
Lewis, T. S.,
P. S. Shapiro, and N. G. Ahn.
1998.
Signal transduction through MAP kinase cascades.
Adv. Cancer Res.
74:74-139.
|
| 29.
|
Lin, A.,
A. Minden,
H. Martinetto,
F.-X. Claret,
C. Lang-Carter,
F. Mercurio,
G. L. Johnson, and M. Karin.
1995.
Identification of a dual specificity kinase that activates the Jun kinases and p38 MPK.
Science
268:286-290[Abstract/Free Full Text].
|
| 30.
|
Liu, B., and M. F. Stinski.
1992.
Human cytomegalovirus contains a tegument protein that enhances transcription from promoters with upstream ATF and AP-1 cis-acting elements.
J. Virol.
66:4434-4444[Abstract/Free Full Text].
|
| 31.
|
Luo, R. X.,
A. A. Postigo, and D. C. Dean.
1998.
Rb interacts with histone deacetylase to repress transcription.
Cell
92:463-473[CrossRef][Medline].
|
| 32.
|
Magnaghi-Jaulin, L.,
R. Groisman,
I. Naguibneva,
P. Robin,
S. Loran,
J. P. Le Villain,
F. Troalen,
D. Trouche, and A. Harel-Bellan.
1998.
Retinoblastoma protein represses transcription by recruiting a histone deacetylase.
Nature (London)
391:601-605[CrossRef][Medline].
|
| 33.
|
Mar, E.-C.,
Y.-C. Cheng, and E.-S. Huang.
1983.
Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on human cytomegalovirus replication in vitro.
Antimicrob. Agents Chemother.
24:518-521[Abstract/Free Full Text].
|
| 34.
|
McLean, T. I., and S. L. Bachenheimer.
1999.
Activation of c-Jun N-terminal kinase by herpes simplex virus type 1 enhances viral replication.
J. Virol.
73:8415-8426[Abstract/Free Full Text].
|
| 35.
|
Meriin, A. B.,
J. A. Yaglom,
V. L. Gabai,
D. D. Mosser,
L. Zon, and M. Y. Sherman.
1999.
Protein-damaging stresses activate c-Jun N-terminal kinase via inhibition of its dephosphorylation: a novel pathway controlled by HSP72.
Mol. Cell. Biol.
19:2547-2555[Abstract/Free Full Text].
|
| 36.
|
Michelson, S.,
P. Turowski,
L. Picard,
J. Goris,
M. P. Landini,
A. Topilko,
B. Hemmings,
C. Bessia,
A. Garcia, and J. L. Virelizier.
1996.
Human cytomegalovirus carries serine/threonine protein phosphatases PP1 and a host-cell derived PP2A.
J. Virol.
70:1415-1423[Abstract].
|
| 37.
|
Mills, J.,
M. A. Jacombson,
J. J. O'Donnell,
D. Cederberg, and G. N. Holland.
1988.
Treatment of cytomegalovirus retinitis in patients with AIDS.
Rev. Infect. Dis.
10(Suppl.):S522-S531.
|
| 38.
|
Minden, A., and M. Karin.
1997.
Regulation and function of the JNK subgroup of MAPK kinases.
Biochim. Biophys. Acta
1333:F85-F104[Medline].
|
| 39.
|
Nevins, J. R.
1998.
Toward an understanding of the functional complexity of the E2F and retinoblastoma families.
Cell Growth Differ.
9:585-593[Medline].
|
| 40.
|
Oberg, B.,
S. Behrnetz,
B. Eriksson,
H. Jozwiak,
A. Larsson,
J. D. Lernestedt, and V. L. Aberg.
1988.
Clinical use of Foscarnet (phosphonoformate), p. 223-240.
In
E. D. Clercq (ed.), Clinical use of antiviral drugs. Martinus Nijhoff, Boston, Mass.
|
| 41.
|
Pallas, D. C.,
L. K. Shahrik,
B. L. Martin,
S. Jaspers,
T. B. Miller,
D. L. Brautigan, and T. M. Roberts.
1990.
Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A.
Cell
60:167-176[CrossRef][Medline].
|
| 42.
|
Popik, W., and P. M. Pitha.
1998.
Early activation of mitogen-activated protein kinase kinase, extracellular signal-regulated kinase, p38 mitogen activated protein kinase, and c-Jun N-terminal kinase in response to binding of simian immunodeficiency virus to Jurkat T cells expressing CCR5 receptor.
Virology
252:210-217[CrossRef][Medline].
|
| 43.
|
Raingeaud, J.,
S. Gupta,
J. S. Rogers,
M. Dickens,
J. Han,
R. J. Ulevitch, and R. J. Davis.
1995.
Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine.
J. Biol. Chem.
270:7420-7426[Abstract/Free Full Text].
|
| 44.
|
Raingeaud, J.,
A. J. Whitmarsh,
T. Barrett,
B. Derijard, and R. J. Davis.
1996.
MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway.
Mol. Cell. Biol.
16:1247-1255[Abstract].
|
| 45.
|
Robinson, M. J., and M. H. Cobb.
1997.
Mitogen-activated protein kinase pathways.
Curr. Opin. Cell Biol.
9:180-186[CrossRef][Medline].
|
| 46.
|
Rodems, S. M., and D. H. Spector.
1998.
Extracellular signal-regulated kinase activity is sustained early during human cytomegalovirus infection.
J. Virol.
72:9173-9180[Abstract/Free Full Text].
|
| 47.
|
Rouse, J.,
P. Cohen,
S. Trigon,
M. Morange,
A. Alonso-Llamazares,
D. Zamanillo,
T. Hunt, and A. R. Nebreda.
1994.
A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins.
Cell
78:1027-1037[CrossRef][Medline].
|
| 48.
|
Shapiro, L.,
K. A. Heidenreich,
M. D. Meintzer, and C. A. Dinarello.
1998.
Role of p38 mitogen-activated protein kinase in HIV type 1 production in vitro.
Proc. Natl. Acad. Sci. USA
95:7422-7426[Abstract/Free Full Text].
|
| 49.
|
Thomson, S.,
L. C. Mahadevan, and A. L. Clayton.
1999.
MAP kinase-mediated signalling to nucleosomes and immediate-early gene induction.
Semin. Cell. Dev. Biol.
10:205-214[CrossRef][Medline].
|
| 50.
|
Wang, S.,
N. Nath,
A. Minden, and S. Chellappan.
1999.
Regulation of Rb and E2F by signal transduction cascades: divergent effects of JNK1 and p38 kinases.
EMBO J.
18:1559-1570[CrossRef][Medline].
|
| 51.
|
Weinberg, R. A.
1995.
The retinoblastoma protein and cell cycle control.
Cell
81:323-330[CrossRef][Medline].
|
| 52.
|
Weitzman, J. B., and M. Yaniv.
1998.
Signal transduction pathways and modulation of gene activity.
Clin. Chem. Lab. Med.
36:535-539[CrossRef][Medline].
|
| 53.
|
Weller, T. H.
1971.
The cytomegaloviruses: ubiquitous agents with protean clinical manifestations.
N. Engl. J. Med.
285:203-214.
|
| 54.
|
Yang, S. I.,
R. L. Lickteig,
R. Estes,
K. Rundell,
G. Walter, and M. C. Mumby.
1991.
Control of protein phosphatase 2A by simian virus 40 small-t antigen.
Mol. Cell. Biol.
11:1988-1995[Abstract/Free Full Text].
|
| 55.
|
Yurochko, A. D., and E.-S. Huang.
1999.
Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression.
J. Immunol.
162:4806-4816[Abstract/Free Full Text].
|
| 56.
|
Yurochko, A. D.,
E.-S. Hwang,
L. Rasmussen,
S. Keay,
L. Pereira, and E.-S. Huang.
1997.
The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF- B during infection.
J. Virol.
71:5051-5059[Abstract].
|
| 57.
|
Yurochko, A. D.,
T. F. Kowalik,
S.-M. Huong, and E.-S. Huang.
1995.
HCMV upregulates NF- B activity by transactivating the NF- B p105/p50 and p65 promoters.
J. Virol.
69:5391-5400[Abstract].
|
| 58.
|
Yurochko, A. D.,
M. W. Mayo,
E. E. Poma,
A. S. Baldwin, Jr., and E.-S. Huang.
1997.
Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF- B promoters.
J. Virol.
71:4638-4648[Abstract].
|
| 59.
|
Zachos, G.,
B. Clements, and J. Conner.
1999.
Herpes simplex virus type 1 infection stimulates p38/c-Jun N-terminal mitogen-activated protein kinase pathways and activates transcription factor AP-1.
J. Biol. Chem.
274:5097-5103[Abstract/Free Full Text].
|
Journal of Virology, February 2000, p. 1158-1167, Vol. 74, No. 3
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kuang, E., Wu, F., Zhu, F.
(2009). Mechanism of Sustained Activation of Ribosomal S6 Kinase (RSK) and ERK by Kaposi Sarcoma-associated Herpesvirus ORF45: MULTIPROTEIN COMPLEXES RETAIN ACTIVE PHOSPHORYLATED ERK AND RSK AND PROTECT THEM FROM DEPHOSPHORYLATION. J. Biol. Chem.
284: 13958-13968
[Abstract]
[Full Text]
-
Machesky, N. J., Zhang, G., Raghavan, B., Zimmerman, P., Kelly, S. L., Merrill, A. H. Jr., Waldman, W. J., Van Brocklyn, J. R., Trgovcich, J.
(2008). Human Cytomegalovirus Regulates Bioactive Sphingolipids. J. Biol. Chem.
283: 26148-26160
[Abstract]
[Full Text]
-
Svensson, R. U., Barnes, J. M., Rokhlin, O. W., Cohen, M. B., Henry, M. D.
(2007). Chemotherapeutic Agents Up-regulate the Cytomegalovirus Promoter: Implications for Bioluminescence Imaging of Tumor Response to Therapy. Cancer Res.
67: 10445-10454
[Abstract]
[Full Text]
-
Jarvis, M. A., Borton, J. A., Keech, A. M., Wong, J., Britt, W. J., Magun, B. E., Nelson, J. A.
(2006). Human Cytomegalovirus Attenuates Interleukin-1{beta} and Tumor Necrosis Factor Alpha Proinflammatory Signaling by Inhibition of NF-{kappa}B Activation.. J. Virol.
80: 5588-5598
[Abstract]
[Full Text]
-
Petrik, D. T., Schmitt, K. P., Stinski, M. F.
(2006). Inhibition of Cellular DNA Synthesis by the Human Cytomegalovirus IE86 Protein Is Necessary for Efficient Virus Replication.. J. Virol.
80: 3872-3883
[Abstract]
[Full Text]
-
Shen, Y. H., Zhang, L., Utama, B., Wang, J., Gan, Y., Wang, X., Wang, J., Chen, L., Vercellotti, G. M., Coselli, J. S., Mehta, J. L., Wang, X. L.
(2006). Human cytomegalovirus inhibits Akt-mediated eNOS activation through upregulating PTEN (phosphatase and tensin homolog deleted on chromosome 10). Cardiovasc Res
69: 502-511
[Abstract]
[Full Text]
-
Noyce, R. S., Collins, S. E., Mossman, K. L.
(2006). Identification of a Novel Pathway Essential for the Immediate-Early, Interferon-Independent Antiviral Response to Enveloped Virions. J. Virol.
80: 226-235
[Abstract]
[Full Text]
-
Walsh, D., Perez, C., Notary, J., Mohr, I.
(2005). Regulation of the Translation Initiation Factor eIF4F by Multiple Mechanisms in Human Cytomegalovirus-Infected Cells. J. Virol.
79: 8057-8064
[Abstract]
[Full Text]
-
Hargett, D., McLean, T., Bachenheimer, S. L.
(2005). Herpes Simplex Virus ICP27 Activation of Stress Kinases JNK and p38. J. Virol.
79: 8348-8360
[Abstract]
[Full Text]
-
Gravel, S.-P., Servant, M. J.
(2005). Roles of an I{kappa}B Kinase-related Pathway in Human Cytomegalovirus-infected Vascular Smooth Muscle Cells: A MOLECULAR LINK IN PATHOGEN-INDUCED PROATHEROSCLEROTIC CONDITIONS. J. Biol. Chem.
280: 7477-7486
[Abstract]
[Full Text]
-
Hertel, L., Mocarski, E. S.
(2004). Global Analysis of Host Cell Gene Expression Late during Cytomegalovirus Infection Reveals Extensive Dysregulation of Cell Cycle Gene Expression and Induction of Pseudomitosis Independent of US28 Function. J. Virol.
78: 11988-12011
[Abstract]
[Full Text]
-
Abate, D. A., Watanabe, S., Mocarski, E. S.
(2004). Major Human Cytomegalovirus Structural Protein pp65 (ppUL83) Prevents Interferon Response Factor 3 Activation in the Interferon Response. J. Virol.
78: 10995-11006
[Abstract]
[Full Text]
-
Gredmark, S., Britt, W. B., Xie, X., Lindbom, L., Soderberg-Naucler, C.
(2004). Human Cytomegalovirus Induces Inhibition of Macrophage Differentiation by Binding to Human Aminopeptidase N/CD13. J. Immunol.
173: 4897-4907
[Abstract]
[Full Text]
-
Hong, G. K., Delecluse, H.-J., Gruffat, H., Morrison, T. E., Feng, W.-H., Sergeant, A., Kenney, S. C.
(2004). The BRRF1 Early Gene of Epstein-Barr Virus Encodes a Transcription Factor That Enhances Induction of Lytic Infection by BRLF1. J. Virol.
78: 4983-4992
[Abstract]
[Full Text]
-
Cooray, S.
(2004). The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival. J. Gen. Virol.
85: 1065-1076
[Abstract]
[Full Text]
-
Casarosa, P., Gruijthuijsen, Y. K., Michel, D., Beisser, P. S., Holl, J., Fitzsimons, C. P., Verzijl, D., Bruggeman, C. A., Mertens, T., Leurs, R., Vink, C., Smit, M. J.
(2003). Constitutive Signaling of the Human Cytomegalovirus-encoded Receptor UL33 Differs from That of Its Rat Cytomegalovirus Homolog R33 by Promiscuous Activation of G Proteins of the Gq, Gi, and Gs Classes. J. Biol. Chem.
278: 50010-50023
[Abstract]
[Full Text]
-
Patrone, M., Percivalle, E., Secchi, M., Fiorina, L., Pedrali-Noy, G., Zoppe, M., Baldanti, F., Hahn, G., Koszinowski, U. H., Milanesi, G., Gallina, A.
(2003). The human cytomegalovirus UL45 gene product is a late, virion-associated protein and influences virus growth at low multiplicities of infection. J. Gen. Virol.
84: 3359-3370
[Abstract]
[Full Text]
-
Baillie, J., Sahlender, D. A., Sinclair, J. H.
(2003). Human Cytomegalovirus Infection Inhibits Tumor Necrosis Factor Alpha (TNF-{alpha}) Signaling by Targeting the 55-Kilodalton TNF-{alpha} Receptor. J. Virol.
77: 7007-7016
[Abstract]
[Full Text]
-
Huang, H., Petkova, S. B., Cohen, A. W., Bouzahzah, B., Chan, J., Zhou, J.-n., Factor, S. M., Weiss, L. M., Krishnamachary, M., Mukherjee, S., Wittner, M., Kitsis, R. N., Pestell, R. G., Lisanti, M. P., Albanese, C., Tanowitz, H. B.
(2003). Activation of Transcription Factors AP-1 and NF-{kappa}B in Murine Chagasic Myocarditis. Infect. Immun.
71: 2859-2867
[Abstract]
[Full Text]
-
Cheeran, M. C.-J., Hu, S., Sheng, W. S., Peterson, P. K., Lokensgard, J. R.
(2003). CXCL10 Production from Cytomegalovirus-Stimulated Microglia Is Regulated by both Human and Viral Interleukin-10. J. Virol.
77: 4502-4515
[Abstract]
[Full Text]
-
Fairley, J. A., Baillie, J., Bain, M., Sinclair, J. H.
(2002). Human cytomegalovirus infection inhibits epidermal growth factor (EGF) signalling by targeting EGF receptors. J. Gen. Virol.
83: 2803-2810
[Abstract]
[Full Text]
-
Chen, Y.-R., Han, J., Kori, R., Kong, A.-N. T., Tan, T.-H.
(2002). Phenylethyl Isothiocyanate Induces Apoptotic Signaling via Suppressing Phosphatase Activity against c-Jun N-terminal Kinase. J. Biol. Chem.
277: 39334-39342
[Abstract]
[Full Text]
-
Burysek, L., Syrovets, T., Simmet, T.
(2002). The Serine Protease Plasmin Triggers Expression of MCP-1 and CD40 in Human Primary Monocytes via Activation of p38 MAPK and Janus Kinase (JAK)/STAT Signaling Pathways. J. Biol. Chem.
277: 33509-33517
[Abstract]
[Full Text]
-
Waldhoer, M., Kledal, T. N., Farrell, H., Schwartz, T. W.
(2002). Murine Cytomegalovirus (CMV) M33 and Human CMV US28 Receptors Exhibit Similar Constitutive Signaling Activities. J. Virol.
76: 8161-8168
[Abstract]
[Full Text]
-
Chen, J., Stinski, M. F.
(2002). Role of Regulatory Elements and the MAPK/ERK or p38 MAPK Pathways for Activation of Human Cytomegalovirus Gene Expression. J. Virol.
76: 4873-4885
[Abstract]
[Full Text]
-
Luo, H., Yanagawa, B., Zhang, J., Luo, Z., Zhang, M., Esfandiarei, M., Carthy, C., Wilson, J. E., Yang, D., McManus, B. M.
(2002). Coxsackievirus B3 Replication Is Reduced by Inhibition of the Extracellular Signal-Regulated Kinase (ERK) Signaling Pathway. J. Virol.
76: 3365-3373
[Abstract]
[Full Text]
-
Khaled, A. R., Moor, A. N., Li, A., Kim, K., Ferris, D. K., Muegge, K., Fisher, R. J., Fliegel, L., Durum, S. K.
(2001). Trophic Factor Withdrawal: p38 Mitogen-Activated Protein Kinase Activates NHE1, Which Induces Intracellular Alkalinization. Mol. Cell. Biol.
21: 7545-7557
[Abstract]
[Full Text]
-
Cinatl, J. Jr, Margraf, S., Vogel, J.-U., Scholz, M., Cinatl, J., Doerr, H. W.
(2001). Human Cytomegalovirus Circumvents NF-{kappa}B Dependence in Retinal Pigment Epithelial Cells. J. Immunol.
167: 1900-1908
[Abstract]
[Full Text]
-
Johnson, R. A., Wang, X., Ma, X.-L., Huong, S.-M., Huang, E.-S.
(2001). Human Cytomegalovirus Up-Regulates the Phosphatidylinositol 3-Kinase (PI3-K) Pathway: Inhibition of PI3-K Activity Inhibits Viral Replication and Virus-Induced Signaling. J. Virol.
75: 6022-6032
[Abstract]
[Full Text]
-
Johnson, R. A., Ma, X.-L., Yurochko, A. D., Huang, E.-S.
(2001). The role of MKK1/2 kinase activity in human cytomegalovirus infection. J. Gen. Virol.
82: 493-497
[Abstract]
[Full Text]
-
Monick, M. M., Staber, J. M., Thomas, K. W., Hunninghake, G. W.
(2001). Respiratory Syncytial Virus Infection Results in Activation of Multiple Protein Kinase C Isoforms Leading to Activation of Mitogen-Activated Protein Kinase. J. Immunol.
166: 2681-2687
[Abstract]
[Full Text]
-
Chen, J., Stinski, M. F.
(2000). Activation of Transcription of the Human Cytomegalovirus Early UL4 Promoter by the Ets Transcription Factor Binding Element. J. Virol.
74: 9845-9857
[Abstract]
[Full Text]
-
Griego, S. D., Weston, C. B., Adams, J. L., Tal-Singer, R., Dillon, S. B.
(2000). Role of p38 Mitogen-Activated Protein Kinase in Rhinovirus-Induced Cytokine Production by Bronchial Epithelial Cells. J. Immunol.
165: 5211-5220
[Abstract]
[Full Text]